| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2009 | WO2009012741A1 Method for the synthesis of a-ring aromatized acetyl minocyclines |
| 01/29/2009 | WO2009012702A1 Use of 4-aniline quinazoline derivative for preparing medicaments |
| 01/29/2009 | WO2009012679A1 2,2,3a,4-TETRAHYDROTHIOCHROMENE[4,3-C]PYRAZOLE COMPOUNDS, PREPARATION METHOD AND USAGE THEREOF |
| 01/29/2009 | WO2009012656A1 Inhibitors for matrix metalloproteinases, pharmaceutical compositions containing them and their uses |
| 01/29/2009 | WO2009012650A1 Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof |
| 01/29/2009 | WO2009012647A1 Preparation methods of quinazoline derivatives and their pharmaceutical uses |
| 01/29/2009 | WO2009012590A1 Therapeutic formulations for the treatment of cold and flu-like symptoms |
| 01/29/2009 | WO2009012573A1 Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 01/29/2009 | WO2009012571A1 Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| 01/29/2009 | WO2009012551A1 Resveratrol complex and process for the preperation |
| 01/29/2009 | WO2009012534A1 Improved organ protection, preservation and recovery |
| 01/29/2009 | WO2008152159A3 6 -acyloxy- 7-meth0xy- 2, 2 -dimethylchromane compounds and their use as pigmentation-regulators |
| 01/29/2009 | WO2008150074A3 The composition comprising the extracts, fractions and the isolated compounds of rhus verniciflua for prevention and treatment of diabetic complications |
| 01/29/2009 | WO2008149201A3 Stable pharmaceutical composition |
| 01/29/2009 | WO2008149177A3 Marine lipid compositions and uses thereof |
| 01/29/2009 | WO2008148801A3 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 01/29/2009 | WO2008146305A3 A pharmaceutical composition having virucidal and spermicidal activity |
| 01/29/2009 | WO2008146156A3 An improved process for the preparation of aripiprazole |
| 01/29/2009 | WO2008146085A3 Inflammation and oxidative stress reducing composition for topical or oral administration |
| 01/29/2009 | WO2008142627A3 Multilayered modified release formulation comprising amoxicillin and clavulanate |
| 01/29/2009 | WO2008142094A4 Triazol compounds for treating biofilm formation |
| 01/29/2009 | WO2008140708A8 Use of hdac inhibitors for treatment of cardiac rhythm disorders |
| 01/29/2009 | WO2008138115A8 Nutritional composition comprising l-carmtme fumarate, red wine extract and saw palmetto extract for maintaining skeletal muscle androgen receptivity |
| 01/29/2009 | WO2008129077A3 Crystalline 1-(cyclohexyloxycarbonyloxy) ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate and a process for its preparation |
| 01/29/2009 | WO2008124849A3 Pyrrolo-pyridine kinase modulators |
| 01/29/2009 | WO2008120207A3 Compositions for nasal delivery |
| 01/29/2009 | WO2008120131A3 Pharmaceutical compositions of diclofenac and misoprostol |
| 01/29/2009 | WO2008112773A3 Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| 01/29/2009 | WO2008110918A3 Erythromycin-based macrolides |
| 01/29/2009 | WO2008109490A3 Nucleic acid compounds for inhibiting chek1 gene expression and uses thereof |
| 01/29/2009 | WO2008109378A3 Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof |
| 01/29/2009 | WO2008109368A4 Nucleic acid compounds for inhibiting vegfr gene expression and uses thereof |
| 01/29/2009 | WO2008107211A3 Novel p2y12 receptor antagonists |
| 01/29/2009 | WO2008104278A8 Imidazo[1,2-a] pyridines and their use as pharmaceuticals |
| 01/29/2009 | WO2008104175A3 Novel phosphodiesterase inhibitors |
| 01/29/2009 | WO2008101469A3 Pharmaceutical preparation for treating metastases |
| 01/29/2009 | WO2008100769A3 Process for selective sulfation of aromatic hydroxyl groups |
| 01/29/2009 | WO2008091375A3 Attenuated salmonella as a delivery system for sirna-based tumor therapy |
| 01/29/2009 | WO2008089453A9 Inhibitors of d-amino acid oxidase |
| 01/29/2009 | WO2008086847A3 Synthesis of chromane derivatives in the presence of ionic liquids |
| 01/29/2009 | WO2008085921A3 Methods for reduction of adipose tissue mass |
| 01/29/2009 | WO2008085074A8 1, 3-dihydroimidazoles for treating cardiovascular disorders |
| 01/29/2009 | WO2008082839A3 Pim kinase inhibitors as cancer chemotherapeutics |
| 01/29/2009 | WO2008075207A3 Anti-infection augmentation foamable compositions and kit and uses thereof |
| 01/29/2009 | WO2008075204A3 Lipoic acid derivatives |
| 01/29/2009 | WO2008075201A3 Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
| 01/29/2009 | WO2008073142A8 Novel inhibitors of beta-lactamase |
| 01/29/2009 | WO2008070733A3 Macrocyclic hepatitis c serine protease inhibitors and uses therefor |
| 01/29/2009 | WO2008063781A3 Chemical compounds as cannabinoid receptor ligands |
| 01/29/2009 | WO2008062470A3 Stabilized controlled release dosage form of gliclazide |
| 01/29/2009 | WO2008060269A3 Quinoline methanol compounds for the treatment and prevention of parasitic infections |
| 01/29/2009 | WO2008059372A3 Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt |
| 01/29/2009 | WO2008049595A9 Trypsin-like serine protease inhibitors, and their preparation and use |
| 01/29/2009 | WO2008046882A3 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
| 01/29/2009 | WO2008040778A3 Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c |
| 01/29/2009 | WO2008035364A3 Process for the preparation of micronized valsartan |
| 01/29/2009 | WO2008023016A3 Galenic formulations of aliskiren |
| 01/29/2009 | WO2008020180A3 Methods of increasing the sensitivity of cancer cells to dna damage |
| 01/29/2009 | WO2008014733A9 Medicament for lct poisoning |
| 01/29/2009 | WO2008005565A9 Antiviral phosphinate compounds |
| 01/29/2009 | WO2008004067A3 Alpha-2-delta-1 selective compounds for disorders of the nervous system |
| 01/29/2009 | WO2007146073A3 Method for enhancing cognitive function |
| 01/29/2009 | WO2007139821A3 Methods of using lrr superfamily genes and proteins |
| 01/29/2009 | WO2007114848A3 Chemical compounds |
| 01/29/2009 | WO2007094986A3 Methods of expressing gam-negative glycosaminoglycosaminoglycan synthase genes in gram-positive hosts |
| 01/29/2009 | WO2007089780A3 Bmx/etk tyrosine kinase gene therapy materials and methods |
| 01/29/2009 | WO2007061661A4 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/29/2009 | US20090031435 SMA Therapy and Cell Based Assay |
| 01/29/2009 | US20090030525 Method for restoring a damaged or degenerated intervertebral disc |
| 01/29/2009 | US20090030257 Anti-microbial photodynamic therapy |
| 01/29/2009 | US20090030209 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,13-dihydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-6,11-diene; antitumor compounds; using low toxic and inexpensive materials; product is readily purified; industrial production |
| 01/29/2009 | US20090030204 Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same |
| 01/29/2009 | US20090030197 Quinoline Intermediates of Receptor Tyrosine Kinase Inhibitors and the Synthesis Thereof |
| 01/29/2009 | US20090030183 Interferon Beta-Like Molecules |
| 01/29/2009 | US20090030088 Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol |
| 01/29/2009 | US20090030086 Antimicrobial agents |
| 01/29/2009 | US20090030085 Use of bis-amines to enhance the antimicrobial activity of aqueous compositions |
| 01/29/2009 | US20090030084 Compositions and Methods of Use of Electron Transport System Inhibitors |
| 01/29/2009 | US20090030083 Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
| 01/29/2009 | US20090030082 SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF |
| 01/29/2009 | US20090030081 Use of lr-90 and lr-102 to overcome insulin resistance |
| 01/29/2009 | US20090030080 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 01/29/2009 | US20090030079 Uses of trientine and penicillamine as countermeasures to metal contamination |
| 01/29/2009 | US20090030078 Therapeutic agent for pain |
| 01/29/2009 | US20090030077 Novel Fenofibrate Formulations and Related Methods of Treatment |
| 01/29/2009 | US20090030076 Prostaglandin derivatives |
| 01/29/2009 | US20090030075 Remedy for and Method of Treating Ischemic Cerebral Stroke |
| 01/29/2009 | US20090030074 Synthesis, polymorphs, and pharmaceutical formulation of faah inhibitors |
| 01/29/2009 | US20090030073 Plant-derived therapeutic agent for malignant |
| 01/29/2009 | US20090030072 Pharmaceutical combination of opioid and prostaglandin compound |
| 01/29/2009 | US20090030071 Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol |
| 01/29/2009 | US20090030070 External preparation for skin containing flavanone derivative |
| 01/29/2009 | US20090030068 Antitumour Compounds |
| 01/29/2009 | US20090030067 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane |
| 01/29/2009 | US20090030066 Small molecules for the protection of pancreatic cells |
| 01/29/2009 | US20090030065 Use of Pde1c and Inhibitors Thereof |
| 01/29/2009 | US20090030064 Sugar-coated preparation |
| 01/29/2009 | US20090030063 Combined pharmaceutical preparation for treatment of type 2 diabetes |
| 01/29/2009 | US20090030062 N-{4-[(1S,5R/1R,5S)-3-azabicyclo[3.1.0]hex-1-yl]phenyl}-4-(1-methylethyl)benzenesulfonamide, used for treating drug abuse and dependence, schizophrenia , sexual disorders and as cognition activators |
| 01/29/2009 | US20090030061 Benzoisoindole Derivatives And Their Use As EP4 Receptor Ligands |